26 May 2015

NIB funds Chr. Hansen’s biotechnology research

Avedøre site in Denmark for colour and culture production. Photo: Chr. Hansen A/S.

NIB and Chr. Hansen Holding A/S have finalised a seven-year loan agreement for EUR 50 million to finance the company’s research and development activities in 2015–2016.

Chr. Hansen’s 2015–2016 R&D programme focuses on identifying microorganisms and optimising them for natural ingredient solutions supplied to the food, health and animal feed industries.

The NIB loan will assist the company in enhancing its bioengineering processes and in developing innovative new products by combining food application expertise with the latest enzyme technology. A number of Chr. Hansen’s products currently in development, such as probiotics, are likely to have a positive impact on human and animal health.

Chr. Hansen is actively collaborating and entering into research partnerships with customers, universities, hospitals and other biotech companies, both in Denmark and elsewhere. Chr. Hansen’s main research facilities are located in Denmark, and it has development services in the USA, France and Germany.

Chr. Hansen A/S, founded in 1874, is a global supplier of bioscience-based ingredients to the food, nutritional, pharmaceutical and agricultural industries. Chr. Hansen has 2,500 employees in over 30 countries.

NIB is an international financial institution owned by eight member countries: Denmark, Estonia, Finland, Iceland, Latvia, Lithuania, Norway and Sweden. The Bank finances private and public projects in and outside the member countries. NIB has the highest possible credit rating, AAA/Aaa, with the leading rating agencies Standard & Poor’s and Moody’s.

For further information, please contact
Vagn Lundhøj, Senior Manager, Origination, at +358 10 618 0370,

Niina Rantti, Communications Officer, at +358 10 618 0265,